ISVD Allosteric Modulators for LRRK2 Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current LRRK2 kinase inhibitors face challenges such as toxicity risks and adverse side effects, particularly with long-term inhibition leading to kidney abnormalities and lung issues, highlighting the need for alternative modulators with high specificity and a different mode of action to effectively treat LRRK2-related disorders like Parkinson's disease.
Innovation Solution
Development of immunoglobulin single variable domains (ISVDs) or Nanobodies that act as allosteric modulators, binding to human LRRK2 outside the ATP pocket, modulating its kinase activity without inducing microtubule association, offering a novel therapeutic approach with potential for reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP-competitive kinase inhibitors are used to inhibit LRRK2 activity, then LRRK2 kinase activity is reduced, but severe kidney abnormalities and lung issues occur due to long-term inhibition
Solution Approach 1:
The patent introduces an allosteric modulator as an intermediary substance that indirectly regulates LRRK2 kinase activity through a binding site distinct from the ATP-competitive inhibitors. This mediator approach allows modulation of enzyme activity without directly competing for the ATP binding pocket, thereby avoiding the toxic side effects associated with traditional kinase inhibitors while maintaining therapeutic efficacy.
Solution Approach 2:
The invention changes the binding parameters by targeting a different site on the LRRK2 protein (allosteric site versus ATP-binding site). This parameter change in binding location fundamentally alters the mechanism of inhibition from direct competitive blockade to indirect allosteric modulation, resulting in a safer pharmacological profile that avoids organ toxicity while preserving the desired kinase activity suppression.
2Reliability
If traditional LRRK2 kinase inhibitors are used, then kinase activity is inhibited, but microtubule relocalization issues and adverse side effects occur
Solution Approach 1:
The allosteric modulator serves as an intermediary that indirectly influences LRRK2 function without directly interfering with its normal cellular localization mechanisms. By binding to a regulatory site rather than the catalytic site, the modulator can suppress kinase activity while allowing the protein to maintain its proper spatial distribution within the cell, thus avoiding microtubule relocalization problems.
Solution Approach 2:
Instead of directly blocking the kinase active site (traditional approach), the invention inverts the strategy by binding to an allosteric regulatory site that indirectly controls kinase activity. This inverted approach achieves the same functional outcome (kinase inhibition) through a different mechanistic pathway that does not disrupt cellular localization.
3Object-affected harmful factors
If high specificity modulators are developed to reduce toxicity, then safety is improved, but the need for alternative modes of action requires novel therapeutic approaches
Solution Approach 1:
The allosteric modulator acts as a specialized intermediary that provides high specificity for LRRK2 regulation. This mediator approach inherently reduces toxicity by avoiding off-target effects associated with ATP-competitive inhibitors, while the complexity of the novel approach is offset by the elegance of the allosteric mechanism that achieves precise molecular recognition and selective modulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ISVD-based allosteric modulators effectively inhibit or increase LRRK2 kinase activity, prevent substrate phosphorylation, and maintain cellular localization, providing a safer and more specific therapeutic option for LRRK2-related diseases by avoiding microtubule relocalization issues associated with traditional inhibitors.
Implementation Method 1
binding agents specifically binding human Leucine-rich Repeat Kinase 2 (LRRK2)... immunoglobulin single variable domains (ISVDs) binding to human LRRK2 with nanomolar affinity
Data Source
AI summary
The present invention relates to binding agents of human Leucine-rich Repeat Kinase 2 (LRRK2). More particular, allosteric modulators of LRRK2 activity have been identified, for targeting LRRK2 in human cells, while leaving LRRK2 subcellular localisation unaffected. Even more specifically, protein binding agents for allosteric modulation of LRRK2 kinase activity are disclosed, comprising immunoglobulin single variable domains (ISVDs) binding to human LRRK2 with nanomolar affinity. The invention thus reveals means and methods for a novel LRRK2 targeting approach through allosteric modulation of its activity for use in treatment of LRRK2-related pathologies, such as Parkinson's disease, as well as for use in detection of LRRK2 in vitro and in vivo, and for use as a diagnostic.